Pro Medicus Limited

The Business

Pro Medicus sells cloud-based medical imaging software to hospitals and radiology groups, mostly in the United States, which supplied $236.8m of the $261.7m in group revenue last financial year. The core product streams diagnostic images to radiologists faster than the compress-and-send technology most competitors still use, and because it needs far less server and storage infrastructure, it runs at margins roughly three times the industry norm. Contracts run five to ten years with minimum volume commitments. Every client that has ever signed remains a client today.

Recent Performance

Revenue grew 22.9% in FY26 (28.4% in constant currency), a deceleration from FY25's 31% growth, though a stronger Australian dollar cost roughly $12m of reported revenue. Sixteen new site implementations went live late in the year, setting up a step-up in FY27. Management also disclosed a miss against its internal EBIT target, forgoing the associated short-term bonus entirely rather than softening the outcome, a signal worth noting for what it says about the honesty of internal reporting.

Outlook

Revenue growth is expected to reaccelerate in FY27 as the sixteen new sites reach their first full year of contribution, before easing over the following few years as the client base matures and US market share gains, while still positive, become incrementally harder to win. EBITDA margins are expected to hold near their current 78% level throughout, meaning earnings growth from here is driven almost entirely by revenue expansion rather than further margin improvement. That shift matters: the easy operating leverage has largely already been captured, so the investment case now rests on how long the growth rate itself can be sustained.

Key Risks

The stock's premium rating is itself the dominant risk. At a high multiple of earnings, the market is pricing in years of near-flawless execution, so any disappointment in growth tends to trigger a re-rating well beyond the size of the earnings miss itself. This is a market pricing risk rather than an operational one, and it sits alongside two more specific threats. A slowdown in US market share gains, most likely visible first in quarterly new contract volumes rather than reported revenue, would weigh on the terminal growth assumption embedded in the current valuation, though the contracted backlog provides a two-to-three-year revenue floor regardless. Separately, a streaming imaging product from Epic, the dominant US hospital records vendor, could erode win rates in the large hospital contracts that drive most of the company's growth; no such product has been announced, but Epic's existing relationships inside the same hospital systems make it the most closely watched competitive threat.

What to Watch

The thesis-defining event is the first-quarter FY27 trading update, which will confirm whether the sixteen new implementations are delivering the revenue step-up built into current forecasts.

• Sep-Nov 2026 Q1 FY27 trading update — validates whether new site go-lives are converting to the revenue growth the market is pricing.
• 12-24 months Australian rate normalisation — a fall in the 10-year bond yield toward its five-year average would be a meaningful positive input for a business valued on long-dated cash flows.

Latest Developments

The FY26 result showed a miss against management's internal EBIT target, with the associated bonus forfeited entirely rather than adjusted down. Sixteen new site implementations completed late in the year set up the FY27 revenue step-up now central to the outlook.

Company Description

Pro Medicus builds and sells Visage 7, a cloud-native platform that lets hospitals store, distribute and view medical images without the heavy on-site servers most rivals require. North America is the core market, contributing roughly 90% of group revenue ($236.8m of $261.7m in FY26), with Australia a smaller, mature base and Europe the newest and fastest-growing segment off a low base, anchored by a reference contract at Heidelberg University Hospital. The business is asset-light: near-zero cost of goods sold, no manufacturing, and revenue tied to per-study transaction fees under long-term contracts.

Where the Growth Is

North America is the growth story, and within it, the driver is market share. Pro Medicus holds roughly 11% of the US enterprise imaging market today, with further gains expected over the next decade, though the pace of share capture is expected to slow from around two percentage points a year toward roughly one. The trajectory of that share curve is the single most important variable in the business: faster-than-expected gains extend the growth runway meaningfully, while a stall below the mid-teens would materially shorten it.

Competitive Position

Every client that has signed with Pro Medicus remains a client today, across the company's entire operating history. That retention rate reflects genuine switching costs: imaging platforms are woven into hospital workflows, and moving away is a multi-year, multi-million-dollar undertaking. The streaming architecture itself is the deeper advantage. It delivers images roughly three times faster than the compress-and-send technology most competitors still run, and it eliminates the server, storage and bandwidth costs that weigh on rival margins. That combination is widening, not narrowing, as the company adds cardiology and pathology modules onto the same platform, deepening the dependency each client has on the system.

Management & Capital Discipline

Capital allocation has been disciplined: a fully franked dividend running at roughly 50% of profit, a modest ongoing share buyback of around $10m a year, and selective strategic stakes (around $192m combined) in adjacent AI and diagnostics companies, all funded without taking on debt. Management's transparency is genuinely unusual: the FY26 result disclosed a miss against an internal EBIT target and forfeited the related bonus outright rather than smoothing the outcome. The honest gap in an otherwise strong governance record is succession: there is no disclosed plan for transitioning leadership away from a founder who has led the company for more than four decades.

Financial Position

Pro Medicus carries no debt and holds a substantial cash and investment balance built up from years of high cash conversion. Combined with a $1.3bn multi-year contracted revenue backlog, the balance sheet gives the company a revenue floor that would comfortably absorb a demand shock. This is not a business that needs to raise capital or manage a debt maturity schedule; the risks to the investment case sit almost entirely in what price the market pays for future growth, not in the company's ability to fund its operations.